Dateline: June 29, 2022, Berlin/Boston Bayer AG announced the launch of its new Research and Innovation Centre at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), further expanding the company’s presence in one of the world’s most innovative pharmaceutical R&D hubs. Bayer’s new precision molecular oncology research study is located in the 62,100 square foot building, which represents an overall $140M USD investment into the area, and is equipped with state-of-the-art labs and offices for the development of novel targeted cancer treatments for patients. The centre also houses a newly formed research group with a focus on applying chemical biology techniques to boost the company’s oncology medication development efforts.
“Our brand-new Bayer research and development centre at Kendall Square is part of our strategy to be at the forefront of clinical discovery and advancement development for better client health care,” explained Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division. “Being a part of this unique development community will help our teams when working with specialists here to create advancement developments for clients.”
Christian Rommel, Member of the Executive Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development, said, “Bayer has a growing neighbourhood of first-rate innovators – from our internal professionals and partners such as Vividion, to our worldwide network of scholastic and market partners, many of which lie right here in the Boston area.” “Our new research and development centre in Kendall Square brings us closer to these partners,” the authors write. “It connects us with fellow researchers and organisations that share our goal of pushing the boundaries of medical development in order to bring transformative health services to patients.”
“We have actually brought a variety of different oncology treatments to clients over the previous years,” said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU. We hope to make a significant contribution to the next era of oncology’s rapid advancement. Our new Kendall Square testing facility, staffed by a committed research team of precision oncology specialists, exemplifies our commitment to investing in cutting-edge cancer treatment innovations.
“At Kendall Square, we discover the innovation-driven companies, entrepreneurship, first-rate academics, advanced research study, development innovations, facilities, and culture to support our tactical objectives,” said Marianne De Backer, MBA, Ph.D., Member of the Executive Committee of the Pharmaceuticals Division and Head of Strategy, Business Development & & Licencing, and Open Innovation at Bayer. It allows us to network with current and future industry leaders in the pharmaceutical field, which helps us build our presence and commitment in this vibrant and expanding community. We hope that by forming long-term partnerships with you, we will speed up our search for ground-breaking therapies and breakthroughs. When we pool our knowledge and abilities, we can make a real difference in people’s lives.
The new building has 100 workstations across two stories, and the company plans to hire for another 50 positions in the following months. In order to expedite the development of game-changing treatments for patients, it is designed to enhance collaboration between Bayer’s research and development divisions, its internal partners like BlueRock Therapeutics, Asklepios BioPharmaceutical (AskBio), and Vividion Therapeutics, and external partners. Along with the new Kendall Square facility in Cambridge, Bayer has established strategic research study partnerships with leading clinical partners in Boston, such as joint labs in the fields of lung illness with Brigham and Women’s Hospital and Massachusetts General Hospital and precision cardiology with the Broad Institute of MIT and Harvard.
The Research and Innovation Centre is also a strategic investment in Bayer’s oncology development, with the dual goals of improving cancer care for patients throughout the world and ensuring the company’s long-term viability. on achieve its goal of being a top 10 oncology company by 2030, Bayer is devoting a sizable portion of its global research and development budget on cancer research. New attempts to help people with cancer take advantage of molecular tests and focused treatments through biomarker screening will be propelled forward by the new accuracy molecular oncology proving ground.
Throughout its 160-year history, Bayer has embraced external development and cooperation, and the company has provided clinical development for clients in areas of high medical necessity. The brand-new centre is expected to contribute to Bayer’s Leaps by Bayer effect investments, which have already safeguarded more than 40 deals in service advancement and licencing and invested $1.5 B USD in collaborations since 2020.
By opening this state-of-the-art facility in the world’s preeminent life sciences hub, Bayer is increasing its presence there. There are about a thousand biotech companies in the Boston-Cambridge area, with Kendall Square serving as the East Coast’s pharmaceutical development epicentre. The company has established offices in Boston, San Francisco, San Diego, and Research Triangle Park, North Carolina, four of the most important hubs for biotechnology in the United States.
Bayer is a multinational corporation that specialises in healthcare and nutrition, two areas of study under the life sciences. Its services and solutions are designed to aid development on a personal and global scale by bolstering efforts to meet the formidable challenges posed by a rapidly expanding and ageing global populace. Bayer is committed to fostering long-term growth and making a positive impact through its offerings. At the same time, the Group plans to boost its earning potential and value creation through research and development. Bayer is a globally recognised brand that stands for quality and reliability. The Group employed around 100,000 people in fiscal 2021, and its sales were 44.1 billion euros. Before the release of any truly original items, R&D investments reached a high of 5.3 billion Euros. Visit www.bayer.com for further details.
Positive statements may be included in this release based on the current assumptions and expectations of Bayer’s management. Actual future results, financial situation, advancement, or performance of the business may vary from the estimates provided here due to a variety of known and unknown risks, uncertainties, and other factors. These factors include those discussed in public reports available on Bayer’s website (www.bayer.com). The company has no responsibility to revise or update these upbeat statements to reflect new information or developments.